Inventor · disambiguated record
David Horne
Also filed as: HORNE DAVID · HORNE DAVID A
58 granted patents·15 pending applications·342 citations·filing 1995–2024
98Inventor score
Top patents by PatentIndex Score
73 records- 0196US8962804B2Meditopes and meditope-binding antibodies and uses thereofWILLIAMS JOHN C·Filed 2012·Granted Feb 24, 2015·96 cites·22 claims
- 0294US9828342B2Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereofHOPE CITY·Filed 2013·Granted Nov 28, 2017·19 cites·8 claims
- 0392US11345656B2PCNA inhibitorsHOPE CITY·Filed 2020·Granted May 31, 2022·2 cites·24 claims
- 0492US9932310B2DNA2 inhibitors for cancer treatmentHOPE CITY·Filed 2017·Granted Apr 3, 2018·5 cites·13 claims
- 0590US12054447B2PCNA inhibitorsHOPE CITY·Filed 2022·Granted Aug 6, 2024·1 cites·20 claims
- 0690US10913706B2PCNA inhibitorsHOPE CITY·Filed 2019·Granted Feb 9, 2021·3 cites·42 claims
- 0790US10173984B2DNA2 inhibitors for cancer treatmentHOPE CITY·Filed 2018·Granted Jan 8, 2019·5 cites·8 claims
- 0890US9669108B2Meditopes and meditope-binding antibodies and uses thereofHOPE CITY·Filed 2014·Granted Jun 6, 2017·9 cites·8 claims
- 0989US11198675B2DNA2 inhibitors for cancer treatmentHOPE CITY·Filed 2020·Granted Dec 14, 2021·2 cites·3 claims
- 1089US10562856B2DNA2 inhibitors for cancer treatmentHOPE CITY·Filed 2018·Granted Feb 18, 2020·3 cites·8 claims
- 1189US10550070B2PCNA inhibitorsHOPE CITY·Filed 2016·Granted Feb 4, 2020·4 cites·22 claims
- 1289US5834609ABicyclic aminoimidazolesUNIV COLUMBIA·Filed 1995·Granted Nov 10, 1998·43 cites·2 claims
- 1388US9126960B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2014·Granted Sep 8, 2015·4 cites·13 claims
- 1488US8372983B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2012·Granted Feb 12, 2013·7 cites·2 claims
- 1588US7956076B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2009·Granted Jun 7, 2011·9 cites·7 claims
- 1686US12435030B2PCNA inhibitorsHOPE CITY·Filed 2024·Granted Oct 7, 2025·0 cites·20 claims
- 1786US8658774B2Meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereofWILLIAMS JOHN C·Filed 2011·Granted Feb 25, 2014·12 cites·8 claims
- 1886US6103899ABicyclic aminoimidazolesUNIV COLUMBIA·Filed 1998·Granted Aug 15, 2000·30 cites·12 claims
- 1985USRE45020ERibonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2013·Granted Jul 15, 2014·5 cites·2 claims
- 2084US10703718B25-bromo-indirubinsHOPE CITY·Filed 2018·Granted Jul 7, 2020·2 cites·18 claims
- 2184US9856273B2ETP derivativesHOPE CITY·Filed 2016·Granted Jan 2, 2018·2 cites·19 claims
- 2284US9527868B2ETP derivativesHOPE CITY·Filed 2015·Granted Dec 27, 2016·3 cites·15 claims
- 2383US8163783B2Ribonucleotide reductase inhibitors and methods of useYEN YUN·Filed 2011·Granted Apr 24, 2012·6 cites·8 claims
- 2480US6528646B2Intermediates for the synthesis of debromohymenialdisine and process thereofUNIV COLUMBIA·Filed 2000·Granted Mar 4, 2003·9 cites·6 claims
- 2579US11230560B2Synthesis of ETP derivativesHOPE CITY·Filed 2018·Granted Jan 25, 2022·1 cites·23 claims
- 2678US11246942B2Meditopes and meditope-binding antibodies and uses thereofHOPE CITY·Filed 2017·Granted Feb 15, 2022·1 cites·7 claims
- 2778US9796692B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2017·Granted Oct 24, 2017·1 cites·19 claims
- 2878US9598385B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2015·Granted Mar 21, 2017·2 cites·20 claims
- 2976US6218549B1Bicyclic aminoimidazolesUNIV COLUMBIA·Filed 1999·Granted Apr 17, 2001·15 cites·15 claims
- 3075US11780815B2DNA2 inhibitors for cancer treatmentHOPE CITY·Filed 2021·Granted Oct 10, 2023·0 cites·14 claims
- 3175US6197954B1Intermediates for the synthesis of debromohymenialdisine and processes thereofUNIV COLUMBIA·Filed 1998·Granted Mar 6, 2001·15 cites·21 claims
- 3274US10246471B2ETP derivativesHOPE CITY·Filed 2017·Granted Apr 2, 2019·1 cites·21 claims
- 3374US2023001003A1Meditopes and meditope-binding antibodies and uses thereofHOPE CITY·Filed 2021·Application pending·0 cites
- 3474US2024425584A1Mechanically interlocking complexesHOPE CITY·Filed 2024·Application pending·0 cites
- 3573US10603328B2Methods of treating advanced prostate cancerHOPE CITY·Filed 2018·Granted Mar 31, 2020·1 cites·35 claims
- 3673US8722698B2Berbamine derivativesHORNE DAVID·Filed 2010·Granted May 13, 2014·2 cites·9 claims
- 3772US2025066418A1Cysteine peptide-enabled antibodiesHOPE CITY·Filed 2024·Application pending·0 cites
- 3870US10822353B2Dithio ETP derivativesHOPE CITY·Filed 2017·Granted Nov 3, 2020·1 cites·34 claims
- 3969US10155732B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2017·Granted Dec 18, 2018·0 cites·20 claims
- 4069US9096844B2Photocleavable linkerHOPE CITY·Filed 2013·Granted Aug 4, 2015·1 cites·19 claims
- 4168US11964941B25-Bromo-indirubinsHOPE CITY·Filed 2020·Granted Apr 23, 2024·0 cites·16 claims
- 4268US2025100962A1Clock activators and uses thereofHOPE CITY·Filed 2024·Application pending·0 cites
- 4367US7615638B2Synthesis of grossularines-1 and analogs thereof and method of useHOPE CITY·Filed 2007·Granted Nov 10, 2009·1 cites·16 claims
- 4466US6841685B2Methods for making bis-heterocyclic alkaloidsOREGON STATE·Filed 2001·Granted Jan 11, 2005·3 cites·6 claims
- 4566US2019161461A1Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2018·Application pending·0 cites
- 4662US2024199631A1Synthesis of human serum albumin conjugateHOPE CITY·Filed 2023·Application pending·0 cites
- 4761US11766442B2T-cell lymphoma treatmentsHOPE CITY·Filed 2018·Granted Sep 26, 2023·0 cites·5 claims
- 4860US11541062B2Methods of treating advanced prostate cancerHOPE CITY·Filed 2020·Granted Jan 3, 2023·0 cites·16 claims
- 4960US9233976B2Berbamine derivativesHOPE CITY·Filed 2014·Granted Jan 12, 2016·0 cites·5 claims
- 5060US2021267948A1Treatment of cancerHOPE CITY·Filed 2020·Application pending·0 cites
Showing the top 50 of 73 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David Horne files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →